RongCan Biotech Plans to Initiate Series A Financing Round

Focusing on the development and industrialization of nucleic acid medicines

Focusing on the development and industrialization of nucleic acid medicines

Focusing on the development and industrialization of nucleic acid medicines

Possesses a proprietary RNA-based Therapeutic Platform (RTP) independently developed for nucleic acid medicines

RongCan Biotech Plans to Initiate Series A Financing Round

Date : 2021-12-01

Prev : RongCan Biotech Has Announced the Completion of Series Pre-A Financing Round, Which Is Led by WuXi AppTec with Participation From Lilly Asia Ventures (LAV)

Next : RongCan Biotech Plans to Cooperate with Zhangjiang Hi-tech Park to Set Up a Management Headquarter